As of June 30, 2023, cash, cash equivalents and short-term investments were $539.1 million, as compared to $583.4 million as of March 31, 2023. The decrease was primarily related to cash utilized in operating activities in advancing the Company’s expended clinical development plans. Based on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of June 30, 2023, will enable the Company to fund operations into the second half of calendar year 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REPL:
- Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
- REPL Upcoming Earnings Report: What to Expect?
- Incyte, Replimune enter clinical collaboration for RP1 and INCB99280 in CSCC
- Replimune Announces Sander Slootweg will Depart from its Board of Directors
- Replimune Group director Sander Slootweg to depart